Results 221 to 230 of about 547,526 (313)

Examining health system stakeholder-reported barriers and solutions to foregut cancer care. [PDF]

Am J Surg
Sanghera J, Liapis I, Nair N, Holland M, Tripathi M, Hearld L, Mehari K, Bhatia S, Fonseca AL.   +8 more
europepmc   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Addressing gender and social inequities: the challenge of metabolic control in women with type 2 diabetes in Quito. [PDF]

Glob Health Action
Flores-Sacoto KM, Sanchez-Del-Hierro GA, Moreno-Piedrahita Hernández FG.   +2 more
europepmc   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

A python's embrace? Insurance and the global clinical trial. [PDF]

Health Res Policy Syst
Winters J.
europepmc   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Estimation of the current healthcare costs of gout in Liaoning Province from 2015 to 2022 based on the SHA2011 accounting system. [PDF]

Front Public Health
Shi X, Zheng F, Wan Q, Chai P, Wang G, Pang Z, Ma Y.   +6 more
europepmc   +1 more source

Low‐intervention clinical trials in Spain: Do they progress?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Low‐Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non‐commercial clinical trials (NCCTs); the mandatory ...
Claudia Erika Delgado‐Espinoza, Mayro J. Cortés Pestana, Kristopher Amaro, Rosa M. Antonijoan, Caridad Pontes   +4 more
wiley   +1 more source

The expectations and influencing factors to choose institutional elder care for older person in the context of future disability: an empirical analysis in China based on Anderson's health behavior model. [PDF]

BMC Geriatr
Heng Y, He Y, Meng Z.
europepmc   +1 more source

Why D\u27Oench, Duhme? An Economic, Legal, and Philosophical Critique of a Failed Bank Policy [PDF]

, 2011
Flint, Richard E.
core   +1 more source